New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
08:15 EDTCOV, BSX, ZMH, MDT, BCR, JNJRepeal of medical device tax pushed by Republicans, Bloomberg says
Republicans are trying to include the repeal of a medical device excise tax that has been opposed by companies such as Medtronic (MDT) and Boston Scientific (BSX) in a package of tax breaks moving through the Senate, reported Bloomberg. Other publicly traded medical device makers include Johnson & Johnson (JNJ), Zimmer (ZMH), Covidien (COV), and C.R. Bard (BCR). Reference Link
News For MDT;BSX;JNJ;ZMH;COV;BCR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 28, 2015
07:02 EDTBSXBoston Scientific reports Q1 adjusted EPS 21c, consensus 21c
Reports Q1 revenue $1.77B, consensus $1.78B
05:51 EDTBSXBoston Scientific drug Eluvia trial meets primary endpoint
Subscribe for More Information
April 27, 2015
16:23 EDTBSXBoston Scientific announces strategic collaboration with Brainlab AG
Subscribe for More Information
15:35 EDTMDTMedtronic announces consent decree with FDA for Synchromed system
Subscribe for More Information
15:31 EDTMDTFDA enters consent decree with Medtronic
The FDA announced the filing of a consent decree against Medtronic and two of the company’s officers—S. Omar Ishrak and Thomas Tefft —for repeatedly failing to correct violations, related to the manufacture of Synchromed II Implantable Infusion Pump Systems, medical devices that deliver medication to treat primary or metastatic cancer, chronic pain and severe spasticity. These violations occurred at the company’s Neuromodulation facilities in Columbia Heights, Minnesota, where the devices are manufactured. The legal action requires the company to stop manufacturing, designing and distributing new Synchromed II Implantable Infusion Pump Systems except in very limited cases, such as when a physician determines that the Synchromed II Implantable Infusion Pump System is medically necessary for a patient’s treatment. The consent decree also requires Medtronic to retain a third-party expert to help develop and submit plans to the FDA to correct violations. The consent decree will remain in effect until the FDA has determined that Medtronic has met all the provisions listed in the consent decree.
15:04 EDTBSXNotable companies reporting before tomorrow's open
Subscribe for More Information
11:02 EDTMDTMedtronic begins clinical study of Endurant Evo AAA strent graft system
Subscribe for More Information
06:19 EDTJNJPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 24, 2015
09:37 EDTBCRC.R. Bard upgraded to Buy from Underperform at BofA/Merrill
BofA/Merrill upgraded C.R. Bard two notches to Buy from Underperform and increased its price target to $200 following Q1 results. The firm sees upside to Bard's drug eluting balloon franchise following the report and recent survey results, and expects the company to utilize its under leverage balance sheet in 2015.
April 23, 2015
17:40 EDTBCRC.R. Bard sees Q2 EPS $2.15-$2.19, consensus $2.18
Subscribe for More Information
17:29 EDTBCRC.R. Bard sees FY15 EPS $8.95-$9.05, consensus $9.00
Guidance provided on Q1 earnings conference call.
16:18 EDTBCRC.R. Bard reports Q1 adjusted EPS $2.10, consensus $2.07
Reports Q1 revenue $819.7M, consensus $813.88M.
14:20 EDTJNJEarnings Watch: Google up close to 8.5% since last earnings report
Subscribe for More Information
11:02 EDTJNJJohnson & Johnson increases dividend by 7.1% to 75c
Subscribe for More Information
10:02 EDTJNJAbbVie says communication with Johnson & Johnson has been 'very positive'
Subscribe for More Information
April 21, 2015
11:02 EDTMDTMedtronic begins enrollment in feasibility study of Valiant Mona LSA system
Medtronic announced the start of a new feasibility study to evaluate the safety and effectiveness of the Valiant Mona LSA branch thoracic stent graft system, an investigational medical device designed to enable a completely endovascular solution for aortic aneurysms encroaching on the left subclavian artery. Cleveland Clinic cardiothoracic surgeon Dr. Eric Roselli successfully completed the first implant in the study on Thursday. He serves as the study's national primary investigator and receives consulting fees and honoraria for teaching from Medtronic. The study aims to enroll 24 subjects at up to seven sites in the United States. The purpose of the study is to characterize the safety and effectiveness of the investigational device acutely and at 30 days.
April 20, 2015
16:09 EDTBSXBoston Scientific announces long-term data underscore safety, efficacy of S-ICD
The Journal of the American College of Cardiology published data confirming the long-term safety and efficacy of the Boston Scientific S-ICD System for patients at risk of sudden cardiac arrest. The study, "Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-year Results from a Pooled Analysis of the IDE Study and EFFORTLESS Registry" was led by Dr. Martin Burke, professor of medicine at the University of Chicago. The analysis combined data from two large S-ICD studies to provide the most comprehensive look at S-ICD System patient outcomes to date. The all-cause mortality rate for the S-ICD patients was 1.6% per year, comparing favorably to observed mortality rates in similar TV-ICD studies. Currently, the S-ICD System is covered nationally by Medicare, Aetna, Cigna and others, and regionally by numerous private and Medicaid plans, providing coverage for approximately 170M individuals in the U.S. The S-ICD System has been commercially available in Europe since 2009.
14:32 EDTJNJPharmacyclics patent for Imbruvica challenged by Hayman Capital's Bass
Subscribe for More Information
07:44 EDTBSXSurvey shows strong momentum for Boston Scientific devices, says RBC Capital
RBC Capital says that its survey supports strong momentum for Boston Scientific's S-ICD and Watchman, and the firm thinks the company is probably gaining share in single-chamber ICDs. The firm raised its price target on the shares to $20 from $17 and recommends buying the shares at current levels or on pullbacks.
06:59 EDTJNJJohnson & Johnson added to short-term buy list at Deutsche Bank
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use